{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(11)"],"submitter":["Ramasamy K"],"funding":["Janssen-Cilag Ltd, Napp and Blood Cancer UK"],"journal":["Blood cancer journal"],"pagination":["162"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9708638"],"repository":["biostudies-literature"],"pubmed_title":["Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial."],"pmcid":["PMC9708638"],"pubmed_authors":["Ramasamy K","Iqbal G","Brouwer R","Stalker V","Schey S","Lindsay J","Akhtar S","Dunn J","Drayson M","Varghese S"],"additional_accession":[]},"is_claimable":false,"name":"Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.","description":null,"dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T09:44:04.23Z","creation":"2025-04-05T09:44:04.23Z"},"accession":"S-EPMC9708638","cross_references":{"pubmed":["36446771"],"doi":["10.1038/s41408-022-00758-7"]}}